RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
GeneQuantum Healthcare of Suzhou closed a nearly $15 million Pre-B financing, led by Huagai Capital and joined by Hofon Capital and Changjinboya. The company plans to use the funds for global clinical development of its next-gen ADCs, as well as the development of a number of differentiated innovative technologies and products. GeneQuantum employs its innovative LDC technology to develop novel bioconjugate drugs and has announced discovery partnerships with MITRO Biotech of Nanjing and Beijing’s Biocytogen.
Source: China Biotoday
